Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -1.38% | |
| 50 DMA Resistance | Bearish | -6.48% | |
| Crossed Above 20 DMA | Bullish | -6.48% | |
| MACD Bullish Signal Line Cross | Bullish | -6.48% | |
| Pocket Pivot | Bullish Swing Setup | -6.48% | |
| Volume Surge | Other | -6.48% | |
| Multiple of Ten Bearish | Other | -6.48% | |
| Gapped Up | Strength | -6.48% | |
| Upper Bollinger Band Touch | Strength | -6.48% | |
| MACD Bearish Signal Line Cross | Bearish | 3.55% |
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| Down 5% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/05/2024
Apellis Pharmaceuticals, Inc. Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Organ Systems Eye Inflammatory Diseases Macular Degeneration Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Hemoglobin Complement System Acquired Hemolytic Anemia Copd Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Intravitreal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 73.8 |
| 52 Week Low | 24.34 |
| Average Volume | 3,310,053 |
| 200-Day Moving Average | 42.54 |
| 50-Day Moving Average | 29.23 |
| 20-Day Moving Average | 28.01 |
| 10-Day Moving Average | 28.28 |
| Average True Range | 1.71 |
| RSI (14) | 45.65 |
| ADX | 18.22 |
| +DI | 29.72 |
| -DI | 25.01 |
| Chandelier Exit (Long, 3 ATRs) | 25.68 |
| Chandelier Exit (Short, 3 ATRs) | 29.46 |
| Upper Bollinger Bands | 30.04 |
| Lower Bollinger Band | 25.99 |
| Percent B (%b) | 0.37 |
| BandWidth | 14.46 |
| MACD Line | -0.39 |
| MACD Signal Line | -0.43 |
| MACD Histogram | 0.0417 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 29.89 | ||||
| Resistance 3 (R3) | 30.12 | 29.55 | 29.49 | ||
| Resistance 2 (R2) | 29.55 | 28.94 | 29.44 | 29.36 | |
| Resistance 1 (R1) | 28.52 | 28.56 | 28.24 | 28.29 | 29.22 |
| Pivot Point | 27.95 | 27.95 | 27.81 | 27.84 | 27.95 |
| Support 1 (S1) | 26.92 | 27.34 | 26.64 | 26.69 | 25.76 |
| Support 2 (S2) | 26.35 | 26.96 | 26.24 | 25.62 | |
| Support 3 (S3) | 25.32 | 26.35 | 25.49 | ||
| Support 4 (S4) | 25.09 |
